Conning Inc. Acquires New Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Conning Inc. acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 868 shares of the medical research company’s stock, valued at approximately $206,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jennison Associates LLC raised its position in IQVIA by 7.3% during the first quarter. Jennison Associates LLC now owns 140,914 shares of the medical research company’s stock valued at $35,636,000 after acquiring an additional 9,578 shares in the last quarter. PGGM Investments raised its position in IQVIA by 55.8% during the second quarter. PGGM Investments now owns 12,073 shares of the medical research company’s stock valued at $2,553,000 after acquiring an additional 4,326 shares in the last quarter. SG Americas Securities LLC raised its position in IQVIA by 80.1% during the first quarter. SG Americas Securities LLC now owns 45,787 shares of the medical research company’s stock valued at $11,579,000 after acquiring an additional 20,369 shares in the last quarter. Quadrature Capital Ltd acquired a new position in IQVIA during the first quarter valued at approximately $3,365,000. Finally, Raymond James & Associates grew its holdings in IQVIA by 0.7% during the second quarter. Raymond James & Associates now owns 800,374 shares of the medical research company’s stock valued at $169,231,000 after purchasing an additional 5,417 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the topic of several analyst reports. TD Cowen lowered their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday. Deutsche Bank Aktiengesellschaft lowered their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a report on Friday. JPMorgan Chase & Co. lowered their price target on IQVIA from $288.00 to $279.00 and set an “overweight” rating on the stock in a report on Wednesday, October 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $270.00 price target on shares of IQVIA in a report on Friday. Finally, Robert W. Baird lowered their price target on IQVIA from $256.00 to $223.00 and set a “neutral” rating on the stock in a report on Friday. Four investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $263.81.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is owned by company insiders.

IQVIA Stock Up 1.6 %

Shares of IQV stock opened at $209.16 on Monday. The stock has a market cap of $38.13 billion, a P/E ratio of 27.45, a price-to-earnings-growth ratio of 2.01 and a beta of 1.51. IQVIA Holdings Inc. has a one year low of $181.03 and a one year high of $261.73. The stock has a fifty day moving average price of $234.31 and a 200 day moving average price of $229.76. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.85.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.